Investors Overview

Corporate Profile
Cipher Pharmaceuticals is a rapidly growing specialty pharmaceutical dermatology company, with a robust and diversified portfolio of commercial and late-stage products. Cipher acquires first-in-class or best-in-class products and transformative compounds that fulfill high unmet medical needs. Our experienced management team has a proven track record of successfully managing the required clinical development and regulatory approval processes and marketing products either directly or through partners. Cipher is well-capitalized to drive sustained earnings growth by leveraging our proven clinical development capabilities and efficient commercial execution. With seven transactions announced in 2015, we are on pace to achieve our goal of expanding our Canadian dermatology franchise, building a U.S. commercial presence and ultimately, becoming the most customer-centric dermatology company in North America.
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.08 (2.17%)
Data as of 10/21/16 3:59 p.m. ET
Refresh quote
ExchangeTSX (Canadian Dollar)
Change (%) Stock is Down 0.01 (0.21%)
Data as of 10/21/16 3:50 p.m. ET
Refresh quote
Recent NewsMore >>
09/01/16Cipher Pharmaceuticals appoints Stephen Lemieux as Chief Financial OfficerPrinter Friendly Version
08/10/16Cipher Pharmaceuticals Reports Q2 2016 Results Highlighted by 32% Revenue Growth and $3.1 Million Cash from OperationsPrinter Friendly Version
08/09/16Cipher Pharmaceuticals Inc. Announces Changes to its Board of DirectorsPrinter Friendly Version
Featured Documents
Download Documentation Q2 Report
Download Documentation Investor Presentation - August 2016
Download Documentation Investor Presentation - June 2016
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Cipher Pharmaceuticals Inc posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources